Brad Shumel
About
Brad Shumel is a scholar working on Dermatology, Immunology and Allergy and Physiology.
According to data from OpenAlex, Brad Shumel has authored 59 papers receiving a total of 1.3k indexed citations (citations by other indexed papers that have themselves been cited), including 50 papers in Dermatology, 38 papers in Immunology and Allergy and 28 papers in Physiology. Recurrent topics in Brad Shumel's work include Dermatology and Skin Diseases (50 papers), Asthma and respiratory diseases (28 papers) and Allergic Rhinitis and Sensitization (27 papers). Brad Shumel is often cited by papers focused on Dermatology and Skin Diseases (50 papers), Asthma and respiratory diseases (28 papers) and Allergic Rhinitis and Sensitization (27 papers). Brad Shumel collaborates with scholars based in United States, Germany and Netherlands. Brad Shumel's co-authors include Neil M.H. Graham, Gianluca Pirozzi, Marjolein de Bruin‐Weller, Laurent Eckert, Diamant Thaçi, Bolanle Akinlade, Allen Radin, Z. Chen, Thomas Hultsch and Marius Ardeleanu and has published in prestigious journals such as SHILAP Revista de lepidopterología, Diabetes Care and Journal of Allergy and Clinical Immunology.
In The Last Decade
Brad Shumel
57 papers receiving 1.3k citations
Hit Papers
Peers
Brad Shumel
Sherief R. Janmohamed United States
Dan Gustafsson Sweden
Elina Holopainen Finland
William Franklin United States
A Hartkamp Netherlands
David H. J. Pols Netherlands
Vincent A. Mukkada United States
Ramón Naranjo‐Sintes Spain
Yun‐Ting Chang Taiwan
Robert Quinet United States
Citations per year, relative to Brad Shumel Brad Shumel (= 1×)
peers
Sherief R. Janmohamed
Countries citing papers authored by Brad Shumel
Since
Specialization
Citations
This map shows the geographic impact of Brad Shumel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Brad Shumel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Brad Shumel more than expected).
Fields of papers citing papers by Brad Shumel
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Brad Shumel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Brad Shumel. The network helps show where Brad Shumel may publish in the future.
Co-authorship network of co-authors of Brad Shumel
This figure shows the co-authorship network connecting the top 25 collaborators of Brad Shumel. A scholar is included among the top collaborators of Brad Shumel based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Brad Shumel. Brad Shumel is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Langley, Richard G., Anna Coleman, Marius Ardeleanu, et al.. (2025). The Safety Data of Dupilumab for the Treatment of Moderate‑to‑Severe Atopic Dermatitis in Infants, Children, Adolescents, and Adults. American Journal of Clinical Dermatology. 26(6). 981–1002.
2.
Siegfried, Elaine C., Lara Wine Lee, Jonathan M. Spergel, et al.. (2024). A case series of live attenuated vaccine administration in dupilumab‐treated children with atopic dermatitis. Pediatric Dermatology. 41(2). 204–209.
3.
Briggs, Emily, Mohamed Kamal, Matthew P. Kosloski, et al.. (2023). Integrated Exposure–Response of Dupilumab in Children, Adolescents, and Adults With Atopic Dermatitis Using Categorical and Continuous Efficacy Assessments: A Population Analysis. Pharmaceutical Research. 40(11). 2653–2666.
4.
Weidinger, Stephan, Eric L. Simpson, Jonathan I. Silverberg, et al.. (2023). Efficacy of dupilumab in moderate and severe atopic dermatitis. SHILAP Revista de lepidopterología. 2(2). 247–260.
5.
Yosipovitch, Gil, Marjolein de Bruin‐Weller, April W. Armstrong, et al.. (2021). Dupilumab Treatment Provides Sustained Improvements Over 2 Years in Symptoms and Quality of Life in Adults with Atopic Dermatitis. Dermatology and Therapy. 11(6). 2147–2157.
6.
Beck, Lisa A., Diamant Thaçi, Mette Deleuran, et al.. (2021). Laboratory safety of dupilumab for up to 3 years in adults with moderate-to-severe atopic dermatitis: results from an open-label extension study. Journal of Dermatological Treatment. 33(3). 1608–1616.
7.
Paller, Amy S., et al.. (2021). IGAxBSA composite for assessing disease severity and response in patients with atopic dermatitis*. British Journal of Dermatology. 186(3). 496–507.
8.
Blauvelt, Andrew, Marjolein de Bruin‐Weller, Eric L. Simpson, et al.. (2021). Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks. Dermatology and Therapy. 12(1). 223–231.
9.
Silverberg, Jonathan I., Eric L. Simpson, Mark Boguniewicz, et al.. (2021). Dupilumab Provides Rapid and Sustained Clinically Meaningful Responses in Adults with Moderate-to-severe Atopic Dermatitis. Acta Dermato Venereologica. 101(11). adv00585–adv00585.
10.
Armstrong, April W., Andrew Blauvelt, Eric L. Simpson, et al.. (2021). Continued Treatment with Dupilumab is Associated with Improved Efficacy in Adults with Moderate-to-Severe Atopic Dermatitis Not Achieving Optimal Responses with Short-Term Treatment. Dermatology and Therapy. 12(1). 195–202.
11.
Bansal, Ashish, Eric L. Simpson, Amy S. Paller, et al.. (2021). Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. American Journal of Clinical Dermatology. 22(1). 101–115.
12.
Wu, Jashin J., Lynda Spelman, Takafumi Etoh, et al.. (2021). Dupilumab Maintains Long-Term Disease Control in Adults with Moderate-to-Severe Atopic Dermatitis as Measured by Well-Controlled Weeks: Results From the LIBERTY AD CHRONOS Clinical Trial. Dermatology and Therapy. 11(2). 327–330.
13.
Barbarot, S., Andreas Wollenberg, Jonathan I. Silverberg, et al.. (2020). Dupilumab provides rapid and sustained improvement in SCORAD outcomes in adults with moderate-to-severe atopic dermatitis: combined results of four randomized phase 3 trials. Journal of Dermatological Treatment. 33(1). 266–277.
14.
Weyne, Jonathan, Andrew Blauvelt, Marjolein de Bruin‐Weller, et al.. (2020). Patient-Reported Ocular Disorders and Symptoms in Adults with Moderate-to-Severe Atopic Dermatitis: Screening and Baseline Survey Data from a Clinical Trial. Dermatology and Therapy. 10(6). 1415–1421.
15.
Beck, Lisa A., Diamant Thaçi, Mette Deleuran, et al.. (2020). Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. American Journal of Clinical Dermatology. 21(4). 567–577.
16.
Boguniewicz, Mark, Diamant Thaçi, Peter Lio, et al.. (2019). Dupilumab Improves Outcomes of Concurrent Asthma and Chronic Sino-Nasal Conditions in Patients With Atopic Dermatitis—a Pooled Analysis of Four Phase 3 Studies (LIBERTY AD SOLO 1 & 2, CHRONOS, and CAFÉ). Journal of Allergy and Clinical Immunology. 143(2). AB123–AB123.
17.
Wollenberg, Andreas, Lisa A. Beck, Andrew Blauvelt, et al.. (2019). Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). British Journal of Dermatology. 182(5). 1120–1135.
18.
Simpson, Eric L., Thomas Bieber, Marjolein de Bruin‐Weller, et al.. (2018). 489 Dupilumab efficacy in atopic dermatitis in four randomized phase 3 trials (liberty ad solo 1&2, chromos, cafe). Journal of Investigative Dermatology. 138(5). S83–S83.
19.
Simon, James A., Sheryl A. Kingsberg, Brad Shumel, et al.. (2013). Efficacy and safety of flibanserin in postmenopausal women with hypoactive sexual desire disorder. Menopause The Journal of The North American Menopause Society. 21(6). 633–640.
20.
Simon, James A., James Liu, Leon Speroff, Brad Shumel, & James P. Symons. (2003). Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. American Journal of Obstetrics and Gynecology. 188(1). 92–99.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Sherief R. Janmohamed Breakdown of academic impact, for papers by Dan Gustafsson Breakdown of academic impact, for papers by Elina Holopainen Breakdown of academic impact, for papers by William Franklin Breakdown of academic impact, for papers by A Hartkamp Breakdown of academic impact, for papers by David H. J. Pols Breakdown of academic impact, for papers by Vincent A. Mukkada Breakdown of academic impact, for papers by Ramón Naranjo‐Sintes Breakdown of academic impact, for papers by Yun‐Ting Chang Breakdown of academic impact, for papers by Robert Quinet